ATE101796T1 - Blutgerinnungshemmende zusammensetzungen aus faktor xa. - Google Patents

Blutgerinnungshemmende zusammensetzungen aus faktor xa.

Info

Publication number
ATE101796T1
ATE101796T1 AT90909958T AT90909958T ATE101796T1 AT E101796 T1 ATE101796 T1 AT E101796T1 AT 90909958 T AT90909958 T AT 90909958T AT 90909958 T AT90909958 T AT 90909958T AT E101796 T1 ATE101796 T1 AT E101796T1
Authority
AT
Austria
Prior art keywords
factor
inactivated
vivo
active
serine
Prior art date
Application number
AT90909958T
Other languages
English (en)
Inventor
Charles T Esmon
Fletcher B Taylor Jr
Original Assignee
Oklahoma Med Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Med Res Found filed Critical Oklahoma Med Res Found
Application granted granted Critical
Publication of ATE101796T1 publication Critical patent/ATE101796T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
AT90909958T 1989-06-14 1990-06-06 Blutgerinnungshemmende zusammensetzungen aus faktor xa. ATE101796T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/367,544 US5120537A (en) 1989-06-14 1989-06-14 Factor xa based anticoagulant compositions
PCT/US1990/003208 WO1990015619A1 (en) 1989-06-14 1990-06-06 FACTOR Xa BASED ANTICOAGULANT COMPOSITIONS

Publications (1)

Publication Number Publication Date
ATE101796T1 true ATE101796T1 (de) 1994-03-15

Family

ID=23447608

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90909958T ATE101796T1 (de) 1989-06-14 1990-06-06 Blutgerinnungshemmende zusammensetzungen aus faktor xa.

Country Status (10)

Country Link
US (1) US5120537A (de)
EP (1) EP0477274B1 (de)
JP (1) JPH0784392B2 (de)
AT (1) ATE101796T1 (de)
AU (1) AU630477B2 (de)
CA (1) CA2060507C (de)
DE (1) DE69006851T2 (de)
DK (1) DK0477274T3 (de)
ES (1) ES2063365T3 (de)
WO (1) WO1990015619A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS136091A3 (en) * 1990-05-10 1992-04-15 Zymo Genetics Agents for determining thrombi and their application
US20040072757A1 (en) * 1990-09-04 2004-04-15 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5597799A (en) * 1990-09-04 1997-01-28 Cor Therapeutics, Inc. Recombinant agents affecting thrombosis
US5278144A (en) * 1990-09-04 1994-01-11 Cor Therapeutics, Inc. Antithrombosis agents
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5861374A (en) * 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
WO1993007491A1 (en) * 1991-10-04 1993-04-15 Board Of Regents Of The University Of Nebraska A soluble thrombomodulin-based one-stage assay for vitamin k-dependent coagulation-inhibiting proteins
US5716795A (en) * 1991-10-04 1998-02-10 Matschiner; John T. Thrombomodulin-based coagulometric assay of the protein C system
US6039944A (en) * 1992-02-28 2000-03-21 Zymogenetics, Inc. Modified Factor VII
US5266462A (en) * 1992-06-03 1993-11-30 Baxter Diagnostics Inc. Measurement of platelet activities
US5589571A (en) * 1994-10-28 1996-12-31 Cor Therapeutics, Inc. Process for production of inhibited forms of activated blood factors
DE59712322D1 (de) * 1996-03-20 2005-06-30 Baxter Ag Pharmazeutisches Präparat zur Behandlung von Blutgerinnungsstörungen
JP4463460B2 (ja) * 1999-11-02 2010-05-19 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｘａ因子阻害剤の活性をモニターするためラッセルクサリヘビ蛇毒誘導血漿Ｘａ因子活性の使用
AU2001257893A1 (en) * 2000-01-13 2001-07-24 Baxter International Inc. Multiple inactivated blood factor anticoagulant composition
AU2002359790A1 (en) * 2001-12-21 2003-07-15 Charlotte Mecklenburg Hospital Authority Doing Business As Carolinas Medical Center Regulation of nad(p)h oxidase growth and transcription in melanoma cells
AU2003237870A1 (en) * 2002-06-07 2003-12-22 The Brigham & Women's Hospital, Inc. Method and composition for inhibing or slowing blood coagulation
WO2005005954A2 (en) * 2003-06-30 2005-01-20 The Brigham & Women's Hospital, Inc. Method, composition and kit for detecting phosphatidylserine (ps) on cell membranes
US9956272B2 (en) 2007-05-30 2018-05-01 Bio Products Laboratory Limited Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same
GB0710321D0 (en) 2007-05-30 2007-07-11 Nhs Blood & Transplant Method
PL3078743T3 (pl) * 2007-09-28 2020-11-02 Portola Pharmaceuticals, Inc. Antidotum dla inhibitorów czynnika XA i sposoby ich stosowania

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
EP0430930B1 (de) * 1985-03-15 1993-09-01 Btg International Limited Faktor IX-Protein
US4832849A (en) * 1988-06-16 1989-05-23 Merrell Dow Pharmaceuticals Inc. Extraction and purification of an anticoagulant principle from the south american leech, haementeria ghilianii

Also Published As

Publication number Publication date
WO1990015619A1 (en) 1990-12-27
DK0477274T3 (da) 1994-03-28
AU630477B2 (en) 1992-10-29
EP0477274A1 (de) 1992-04-01
CA2060507A1 (en) 1990-12-15
DE69006851T2 (de) 1994-06-30
EP0477274B1 (de) 1994-02-23
JPH04505765A (ja) 1992-10-08
AU5922690A (en) 1991-01-08
ES2063365T3 (es) 1995-01-01
DE69006851D1 (de) 1994-03-31
CA2060507C (en) 1996-12-10
US5120537A (en) 1992-06-09
JPH0784392B2 (ja) 1995-09-13

Similar Documents

Publication Publication Date Title
ATE101796T1 (de) Blutgerinnungshemmende zusammensetzungen aus faktor xa.
Sabatini et al. Mechanisms regulating the degradation of dentin matrices by endogenous dentin proteases and their role in dental adhesion. A review
Hedner et al. Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors.
Bell Jr Defibrinogenating enzymes
Esmon The regulation of natural anticoagulant pathways
Himber et al. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function
DE69131292T2 (de) Antikoagulierende proteine
ES2018729A6 (es) Un metodo para preparar una variante de activador de plasmogeno de tejido.
Kini et al. Inhibition of platelet aggregation by a fibrinogenase from Naja nigricollis venom is independent of fibrinogen degradation
SAWYER et al. Thrombolytic therapy: basic and therapeutic considerations
Mosesson Fibrinogen catabolic pathways
Glazer et al. Clinical update on the use of recombinant factor VII
Aronson Factor IX complex
Benedict et al. Active site-blocked factor Xa prevents thrombus formation in the coronary vasculature in parallel with inhibition of extravascular coagulation in a canine thrombosis model
Gasmi et al. Further characterization and thrombolytic activity in a rat model of a fibrinogenase from Vipera lebetina venom
DE59002760D1 (de) K2p pro-stabilisierung.
Briet et al. Cleavage and activation of human prothrombin by Echiscarinatus venom
Katsuura et al. Characteristic effects of activated human protein C on tissue thromboplastin-induced disseminated intravascular coagulation in rabbits
Walker Interactions of protein S with membranes
ATE268380T1 (de) Thrombin zusammensetzung
Grotto et al. Effect of purified Vipera palestinae hemorrhagin on blood coagulation and platelet function
Weinstein et al. Enhancement of rabbit protein S anticoagulant cofactor activity in vivo by modulation of the protein S C4B binding protein interaction.
McNicol Disordered fibrinolytic activity and its control
NO913118L (no) T-pa pro stabilisering.
Chang et al. The reaction of thrombin with platelet-derived nexin requires a secondary recognition site in addition to the catalytic site

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee